The global Peptide API CDMO Services market was valued at US$ 2682 million in 2025 and is anticipated to reach US$ 7088 million by 2032, at a CAGR of 15.1% from 2026 to 2032.

Peptide API CDMO Services Market

Peptide API CDMO services refer to integrated outsourced solutions that support pharmaceutical companies in process development, scale-up, and commercial manufacturing of peptide active pharmaceutical ingredients. These services cover solid-phase and liquid-phase synthesis, purification, analytical method development, and quality release testing, serving innovative drug developers, generic drug manufacturers, and biotechnology companies. Driven by the expanding peptide drug pipeline, rising outsourcing penetration, and increasing compliance requirements, the market continues to grow, with an industry-average gross margin typically in the range of 25%–35%, reflecting stable profitability.

The current market for peptide API CDMO services is experiencing steady expansion, driven primarily by the growing adoption of peptide therapeutics across metabolic, oncology, and autoimmune indications, as well as stricter regulatory requirements that push pharmaceutical companies to collaborate with highly compliant service providers. Competition has shifted from basic manufacturing capabilities to comprehensive strengths involving process development, complex sequence synthesis, and commercial-scale delivery. Leading players differentiate themselves through platform technologies, automation upgrades, and global execution capacity, while rising outsourcing penetration improves project conversion and strengthens long-term client relationships.

Looking ahead, the market is expected to maintain strong momentum as innovations in targets, delivery systems, and long-acting technologies enrich peptide drug pipelines and create greater demand for high-quality development and manufacturing services. Top-tier CDMO companies will continue investing in continuous flow chemistry, high-throughput screening, and greener synthetic routes to enhance efficiency for complex molecules and large-scale commercial orders. Meanwhile, global regulatory trends emphasize supply chain security, traceability, and consistent quality systems, strengthening the position of companies with cross-regional compliance capabilities. The industry is likely to evolve toward greater specialization and platform-based service structures.

Multiple factors contribute to market growth, including increasing complexity and volume of R&D pipelines, which demands shorter development timelines and higher quality standards; the mainstreaming of outsourcing as pharmaceutical companies seek to optimize costs by reducing internal capacity investment; and the need for multinational firms to secure long-term, reliable global supply partners, benefiting advanced CDMO providers. Continued capital inflows also support capacity expansion, technology upgrades, and consolidation, enhancing the overall market ecosystem.

However, the industry also faces notable challenges. Fluctuating prices of high-end raw materials may exert cost pressure, while long development cycles and high technical barriers for complex peptides can impact project timelines. Regulatory inconsistencies and complex cross-border approval processes add difficulty to global delivery. Long construction cycles, significant capital requirements, and stringent quality system demands constrain rapid scaling for smaller players, while intensifying competition may trigger pricing pressure in lower-value segments. Overall, opportunities and challenges coexist, and the sector is steadily advancing toward higher technological sophistication, stricter quality standards, and more resilient supply chains.

This report delivers a comprehensive overview of the global Peptide API CDMO Services market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Peptide API CDMO Services. The Peptide API CDMO Services market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global Peptide API CDMO Services market comprehensively. Regional market sizes by Type, by Application, by Synthesis Technology, and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist Peptide API CDMO Services manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Market Segmentation

Scope of Peptide API CDMO Services Market Report

Report Metric	Details
Report Name	Peptide API CDMO Services Market
Accounted market size in 2025	US$ 2682 million
Forecasted market size in 2032	US$ 7088 million
CAGR	15.1%
Base Year	2025
Forecasted years	2026 - 2032
Segment by Type	GMP Services Non-GMP Services
Segment by Synthesis Technology	SPPS LPPS Hybrid Technology
Segment by Capacity Tier	Small-Scale (mg–g) Medium-Scale (g–kg) Large-Scale (kg–t)
Segment by Application	Commercial Scientific Research Other
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	PolyPeptide, Bachem, AmbioPharm, CordenPharma, CPC Scientific, Piramal Pharma Solutions, Almac Group, Vtides Life Sciences, Aspen Holdings, Neuland Laboratories, USV, Aurigene Pharmaceutical Services, CBL, Provepharm, PeptiStar, Creative Peptides, Space Peptides, Cambrex, ScinoPharm, Chinese Peptide Company, ChengDu ShengNuo Biotec, WuXi TIDES, Genscript
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, by Synthesis Technology, etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Peptide API CDMO Services companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.

FAQ for this report

How fast is Peptide API CDMO Services Market growing?

Ans: The Peptide API CDMO Services Market witnessing a CAGR of 15.1% during the forecast period 2026-2032.

What is the Peptide API CDMO Services Market size in 2032?

Ans: The Peptide API CDMO Services Market size in 2032 will be US$ 7088 million.

Who are the main players in the Peptide API CDMO Services Market report?

Ans: The main players in the Peptide API CDMO Services Market are PolyPeptide, Bachem, AmbioPharm, CordenPharma, CPC Scientific, Piramal Pharma Solutions, Almac Group, Vtides Life Sciences, Aspen Holdings, Neuland Laboratories, USV, Aurigene Pharmaceutical Services, CBL, Provepharm, PeptiStar, Creative Peptides, Space Peptides, Cambrex, ScinoPharm, Chinese Peptide Company, ChengDu ShengNuo Biotec, WuXi TIDES, Genscript

What are the Application segmentation covered in the Peptide API CDMO Services Market report?

Ans: The Applications covered in the Peptide API CDMO Services Market report are Commercial, Scientific Research, Other

What are the Type segmentation covered in the Peptide API CDMO Services Market report?

Ans: The Types covered in the Peptide API CDMO Services Market report are GMP Services, Non-GMP Services

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Peptide API CDMO Services Market Size Growth Rate by Type: 2021 vs 2025 vs 2032

1.2.2 GMP Services

1.2.3 Non-GMP Services

1.3 Market by Synthesis Technology

1.3.1 Global Peptide API CDMO Services Market Size Growth Rate by Synthesis Technology: 2021 vs 2025 vs 2032

1.3.2 SPPS

1.3.3 LPPS

1.3.4 Hybrid Technology

1.4 Market by Capacity Tier

1.4.1 Global Peptide API CDMO Services Market Size Growth Rate by Capacity Tier: 2021 vs 2025 vs 2032

1.4.2 Small-Scale (mg–g)

1.4.3 Medium-Scale (g–kg)

1.4.4 Large-Scale (kg–t)

1.5 Market by Application

1.5.1 Global Peptide API CDMO Services Market Growth by Application: 2021 vs 2025 vs 2032

1.5.2 Commercial

1.5.3 Scientific Research

1.5.4 Other

1.6 Assumptions and Limitations

1.7 Study Objectives

1.8 Years Considered

2 Global Growth Trends

2.1 Global Peptide API CDMO Services Market Perspective (2021–2032)

2.2 Global Peptide API CDMO Services Growth Trends by Region

2.2.1 Global Peptide API CDMO Services Market Size by Region: 2021 vs 2025 vs 2032

2.2.2 Peptide API CDMO Services Historic Market Size by Region (2021–2026)

2.2.3 Peptide API CDMO Services Forecasted Market Size by Region (2027–2032)

2.3 Peptide API CDMO Services Market Dynamics

2.3.1 Peptide API CDMO Services Industry Trends

2.3.2 Peptide API CDMO Services Market Drivers

2.3.3 Peptide API CDMO Services Market Challenges

2.3.4 Peptide API CDMO Services Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Peptide API CDMO Services Players by Revenue

3.1.1 Global Top Peptide API CDMO Services Players by Revenue (2021–2026)

3.1.2 Global Peptide API CDMO Services Revenue Market Share by Players (2021–2026)

3.2 Global Top Peptide API CDMO Services Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

3.3 Global Key Players Ranking by Peptide API CDMO Services Revenue

3.4 Global Peptide API CDMO Services Market Concentration Ratio

3.4.1 Global Peptide API CDMO Services Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Peptide API CDMO Services Revenue in 2025

3.5 Global Key Players of Peptide API CDMO Services Head Offices and Areas Served

3.6 Global Key Players of Peptide API CDMO Services, Products and Applications

3.7 Global Key Players of Peptide API CDMO Services, Date of General Availability (GA)

3.8 Mergers and Acquisitions, Expansion Plans

4 Peptide API CDMO Services Breakdown Data by Type

4.1 Global Peptide API CDMO Services Historic Market Size by Type (2021–2026)

4.2 Global Peptide API CDMO Services Forecasted Market Size by Type (2027–2032)

5 Peptide API CDMO Services Breakdown Data by Application

5.1 Global Peptide API CDMO Services Historic Market Size by Application (2021–2026)

5.2 Global Peptide API CDMO Services Forecasted Market Size by Application (2027–2032)

6 North America

6.1 North America Peptide API CDMO Services Market Size (2021–2032)

6.2 North America Peptide API CDMO Services Market Growth Rate by Country: 2021 vs 2025 vs 2032

6.3 North America Peptide API CDMO Services Market Size by Country (2021–2026)

6.4 North America Peptide API CDMO Services Market Size by Country (2027–2032)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Peptide API CDMO Services Market Size (2021–2032)

7.2 Europe Peptide API CDMO Services Market Growth Rate by Country: 2021 vs 2025 vs 2032

7.3 Europe Peptide API CDMO Services Market Size by Country (2021–2026)

7.4 Europe Peptide API CDMO Services Market Size by Country (2027–2032)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Ireland

8 Asia-Pacific

8.1 Asia-Pacific Peptide API CDMO Services Market Size (2021–2032)

8.2 Asia-Pacific Peptide API CDMO Services Market Growth Rate by Region: 2021 vs 2025 vs 2032

8.3 Asia-Pacific Peptide API CDMO Services Market Size by Region (2021–2026)

8.4 Asia-Pacific Peptide API CDMO Services Market Size by Region (2027–2032)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia & New Zealand

9 Latin America

9.1 Latin America Peptide API CDMO Services Market Size (2021–2032)

9.2 Latin America Peptide API CDMO Services Market Growth Rate by Country: 2021 vs 2025 vs 2032

9.3 Latin America Peptide API CDMO Services Market Size by Country (2021–2026)

9.4 Latin America Peptide API CDMO Services Market Size by Country (2027–2032)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Peptide API CDMO Services Market Size (2021–2032)

10.2 Middle East & Africa Peptide API CDMO Services Market Growth Rate by Country: 2021 vs 2025 vs 2032

10.3 Middle East & Africa Peptide API CDMO Services Market Size by Country (2021–2026)

10.4 Middle East & Africa Peptide API CDMO Services Market Size by Country (2027–2032)

10.5 Israel

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 PolyPeptide

11.1.1 PolyPeptide Company Details

11.1.2 PolyPeptide Business Overview

11.1.3 PolyPeptide Peptide API CDMO Services Introduction

11.1.4 PolyPeptide Revenue in Peptide API CDMO Services Business (2021–2026)

11.1.5 PolyPeptide Recent Development

11.2 Bachem

11.2.1 Bachem Company Details

11.2.2 Bachem Business Overview

11.2.3 Bachem Peptide API CDMO Services Introduction

11.2.4 Bachem Revenue in Peptide API CDMO Services Business (2021–2026)

11.2.5 Bachem Recent Development

11.3 AmbioPharm

11.3.1 AmbioPharm Company Details

11.3.2 AmbioPharm Business Overview

11.3.3 AmbioPharm Peptide API CDMO Services Introduction

11.3.4 AmbioPharm Revenue in Peptide API CDMO Services Business (2021–2026)

11.3.5 AmbioPharm Recent Development

11.4 CordenPharma

11.4.1 CordenPharma Company Details

11.4.2 CordenPharma Business Overview

11.4.3 CordenPharma Peptide API CDMO Services Introduction

11.4.4 CordenPharma Revenue in Peptide API CDMO Services Business (2021–2026)

11.4.5 CordenPharma Recent Development

11.5 CPC Scientific

11.5.1 CPC Scientific Company Details

11.5.2 CPC Scientific Business Overview

11.5.3 CPC Scientific Peptide API CDMO Services Introduction

11.5.4 CPC Scientific Revenue in Peptide API CDMO Services Business (2021–2026)

11.5.5 CPC Scientific Recent Development

11.6 Piramal Pharma Solutions

11.6.1 Piramal Pharma Solutions Company Details

11.6.2 Piramal Pharma Solutions Business Overview

11.6.3 Piramal Pharma Solutions Peptide API CDMO Services Introduction

11.6.4 Piramal Pharma Solutions Revenue in Peptide API CDMO Services Business (2021–2026)

11.6.5 Piramal Pharma Solutions Recent Development

11.7 Almac Group

11.7.1 Almac Group Company Details

11.7.2 Almac Group Business Overview

11.7.3 Almac Group Peptide API CDMO Services Introduction

11.7.4 Almac Group Revenue in Peptide API CDMO Services Business (2021–2026)

11.7.5 Almac Group Recent Development

11.8 Vtides Life Sciences

11.8.1 Vtides Life Sciences Company Details

11.8.2 Vtides Life Sciences Business Overview

11.8.3 Vtides Life Sciences Peptide API CDMO Services Introduction

11.8.4 Vtides Life Sciences Revenue in Peptide API CDMO Services Business (2021–2026)

11.8.5 Vtides Life Sciences Recent Development

11.9 Aspen Holdings

11.9.1 Aspen Holdings Company Details

11.9.2 Aspen Holdings Business Overview

11.9.3 Aspen Holdings Peptide API CDMO Services Introduction

11.9.4 Aspen Holdings Revenue in Peptide API CDMO Services Business (2021–2026)

11.9.5 Aspen Holdings Recent Development

11.10 Neuland Laboratories

11.10.1 Neuland Laboratories Company Details

11.10.2 Neuland Laboratories Business Overview

11.10.3 Neuland Laboratories Peptide API CDMO Services Introduction

11.10.4 Neuland Laboratories Revenue in Peptide API CDMO Services Business (2021–2026)

11.10.5 Neuland Laboratories Recent Development

11.11 USV

11.11.1 USV Company Details

11.11.2 USV Business Overview

11.11.3 USV Peptide API CDMO Services Introduction

11.11.4 USV Revenue in Peptide API CDMO Services Business (2021–2026)

11.11.5 USV Recent Development

11.12 Aurigene Pharmaceutical Services

11.12.1 Aurigene Pharmaceutical Services Company Details

11.12.2 Aurigene Pharmaceutical Services Business Overview

11.12.3 Aurigene Pharmaceutical Services Peptide API CDMO Services Introduction

11.12.4 Aurigene Pharmaceutical Services Revenue in Peptide API CDMO Services Business (2021–2026)

11.12.5 Aurigene Pharmaceutical Services Recent Development

11.13 CBL

11.13.1 CBL Company Details

11.13.2 CBL Business Overview

11.13.3 CBL Peptide API CDMO Services Introduction

11.13.4 CBL Revenue in Peptide API CDMO Services Business (2021–2026)

11.13.5 CBL Recent Development

11.14 Provepharm

11.14.1 Provepharm Company Details

11.14.2 Provepharm Business Overview

11.14.3 Provepharm Peptide API CDMO Services Introduction

11.14.4 Provepharm Revenue in Peptide API CDMO Services Business (2021–2026)

11.14.5 Provepharm Recent Development

11.15 PeptiStar

11.15.1 PeptiStar Company Details

11.15.2 PeptiStar Business Overview

11.15.3 PeptiStar Peptide API CDMO Services Introduction

11.15.4 PeptiStar Revenue in Peptide API CDMO Services Business (2021–2026)

11.15.5 PeptiStar Recent Development

11.16 Creative Peptides

11.16.1 Creative Peptides Company Details

11.16.2 Creative Peptides Business Overview

11.16.3 Creative Peptides Peptide API CDMO Services Introduction

11.16.4 Creative Peptides Revenue in Peptide API CDMO Services Business (2021–2026)

11.16.5 Creative Peptides Recent Development

11.17 Space Peptides

11.17.1 Space Peptides Company Details

11.17.2 Space Peptides Business Overview

11.17.3 Space Peptides Peptide API CDMO Services Introduction

11.17.4 Space Peptides Revenue in Peptide API CDMO Services Business (2021–2026)

11.17.5 Space Peptides Recent Development

11.18 Cambrex

11.18.1 Cambrex Company Details

11.18.2 Cambrex Business Overview

11.18.3 Cambrex Peptide API CDMO Services Introduction

11.18.4 Cambrex Revenue in Peptide API CDMO Services Business (2021–2026)

11.18.5 Cambrex Recent Development

11.19 ScinoPharm

11.19.1 ScinoPharm Company Details

11.19.2 ScinoPharm Business Overview

11.19.3 ScinoPharm Peptide API CDMO Services Introduction

11.19.4 ScinoPharm Revenue in Peptide API CDMO Services Business (2021–2026)

11.19.5 ScinoPharm Recent Development

11.20 Chinese Peptide Company

11.20.1 Chinese Peptide Company Company Details

11.20.2 Chinese Peptide Company Business Overview

11.20.3 Chinese Peptide Company Peptide API CDMO Services Introduction

11.20.4 Chinese Peptide Company Revenue in Peptide API CDMO Services Business (2021–2026)

11.20.5 Chinese Peptide Company Recent Development

11.21 ChengDu ShengNuo Biotec

11.21.1 ChengDu ShengNuo Biotec Company Details

11.21.2 ChengDu ShengNuo Biotec Business Overview

11.21.3 ChengDu ShengNuo Biotec Peptide API CDMO Services Introduction

11.21.4 ChengDu ShengNuo Biotec Revenue in Peptide API CDMO Services Business (2021–2026)

11.21.5 ChengDu ShengNuo Biotec Recent Development

11.22 WuXi TIDES

11.22.1 WuXi TIDES Company Details

11.22.2 WuXi TIDES Business Overview

11.22.3 WuXi TIDES Peptide API CDMO Services Introduction

11.22.4 WuXi TIDES Revenue in Peptide API CDMO Services Business (2021–2026)

11.22.5 WuXi TIDES Recent Development

11.23 Genscript

11.23.1 Genscript Company Details

11.23.2 Genscript Business Overview

11.23.3 Genscript Peptide API CDMO Services Introduction

11.23.4 Genscript Revenue in Peptide API CDMO Services Business (2021–2026)

11.23.5 Genscript Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Bachem

PolyPeptide

CordenPharma

GenScript

ScinoPharm

CBL

CPC Scientific

AmbioPharm

Chinese Peptide Company

ChengDu ShengNuo Biotec

Piramal Pharma Solutions

Aurigene Pharmaceutical Services

List of Tables

Table 1. Global Peptide API CDMO Services Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032

Table 2. Key Players of GMP Services

Table 3. Key Players of Non-GMP Services

Table 4. Global Peptide API CDMO Services Market Size Growth Rate by Synthesis Technology (US$ Million): 2021 vs 2025 vs 2032

Table 5. Key Players of SPPS

Table 6. Key Players of LPPS

Table 7. Key Players of Hybrid Technology

Table 8. Global Peptide API CDMO Services Market Size Growth Rate by Capacity Tier (US$ Million): 2021 vs 2025 vs 2032

Table 9. Key Players of Small-Scale (mg–g)

Table 10. Key Players of Medium-Scale (g–kg)

Table 11. Key Players of Large-Scale (kg–t)

Table 12. Global Peptide API CDMO Services Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032

Table 13. Global Peptide API CDMO Services Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Table 14. Global Peptide API CDMO Services Market Size by Region (US$ Million), 2021–2026

Table 15. Global Peptide API CDMO Services Market Share by Region (2021–2026)

Table 16. Global Peptide API CDMO Services Forecasted Market Size by Region (US$ Million), 2027–2032

Table 17. Global Peptide API CDMO Services Market Share by Region (2027–2032)

Table 18. Peptide API CDMO Services Market Trends

Table 19. Peptide API CDMO Services Market Drivers

Table 20. Peptide API CDMO Services Market Challenges

Table 21. Peptide API CDMO Services Market Restraints

Table 22. Global Peptide API CDMO Services Revenue by Players (US$ Million), 2021–2026

Table 23. Global Peptide API CDMO Services Market Share by Players (2021–2026)

Table 24. Global Top Peptide API CDMO Services Players by Tier (Tier 1, Tier 2, and Tier 3), based on Peptide API CDMO Services Revenue, 2025

Table 25. Ranking of Global Top Peptide API CDMO Services Companies by Revenue (US$ Million) in 2025

Table 26. Global 5 Largest Players Market Share by Peptide API CDMO Services Revenue (CR5 and HHI), 2021–2026

Table 27. Global Key Players of Peptide API CDMO Services, Headquarters and Area Served

Table 28. Global Key Players of Peptide API CDMO Services, Products and Applications

Table 29. Global Key Players of Peptide API CDMO Services, Date of General Availability (GA)

Table 30. Mergers and Acquisitions, Expansion Plans

Table 31. Global Peptide API CDMO Services Market Size by Type (US$ Million), 2021–2026

Table 32. Global Peptide API CDMO Services Revenue Market Share by Type (2021–2026)

Table 33. Global Peptide API CDMO Services Forecasted Market Size by Type (US$ Million), 2027–2032

Table 34. Global Peptide API CDMO Services Revenue Market Share by Type (2027–2032)

Table 35. Global Peptide API CDMO Services Market Size by Application (US$ Million), 2021–2026

Table 36. Global Peptide API CDMO Services Revenue Market Share by Application (2021–2026)

Table 37. Global Peptide API CDMO Services Forecasted Market Size by Application (US$ Million), 2027–2032

Table 38. Global Peptide API CDMO Services Revenue Market Share by Application (2027–2032)

Table 39. North America Peptide API CDMO Services Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 40. North America Peptide API CDMO Services Market Size by Country (US$ Million), 2021–2026

Table 41. North America Peptide API CDMO Services Market Size by Country (US$ Million), 2027–2032

Table 42. Europe Peptide API CDMO Services Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 43. Europe Peptide API CDMO Services Market Size by Country (US$ Million), 2021–2026

Table 44. Europe Peptide API CDMO Services Market Size by Country (US$ Million), 2027–2032

Table 45. Asia-Pacific Peptide API CDMO Services Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032

Table 46. Asia-Pacific Peptide API CDMO Services Market Size by Region (US$ Million), 2021–2026

Table 47. Asia-Pacific Peptide API CDMO Services Market Size by Region (US$ Million), 2027–2032

Table 48. Latin America Peptide API CDMO Services Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 49. Latin America Peptide API CDMO Services Market Size by Country (US$ Million), 2021–2026

Table 50. Latin America Peptide API CDMO Services Market Size by Country (US$ Million), 2027–2032

Table 51. Middle East & Africa Peptide API CDMO Services Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 52. Middle East & Africa Peptide API CDMO Services Market Size by Country (US$ Million), 2021–2026

Table 53. Middle East & Africa Peptide API CDMO Services Market Size by Country (US$ Million), 2027–2032

Table 54. PolyPeptide Company Details

Table 55. PolyPeptide Business Overview

Table 56. PolyPeptide Peptide API CDMO Services Product

Table 57. PolyPeptide Revenue in Peptide API CDMO Services Business (US$ Million), 2021–2026

Table 58. PolyPeptide Recent Development

Table 59. Bachem Company Details

Table 60. Bachem Business Overview

Table 61. Bachem Peptide API CDMO Services Product

Table 62. Bachem Revenue in Peptide API CDMO Services Business (US$ Million), 2021–2026

Table 63. Bachem Recent Development

Table 64. AmbioPharm Company Details

Table 65. AmbioPharm Business Overview

Table 66. AmbioPharm Peptide API CDMO Services Product

Table 67. AmbioPharm Revenue in Peptide API CDMO Services Business (US$ Million), 2021–2026

Table 68. AmbioPharm Recent Development

Table 69. CordenPharma Company Details

Table 70. CordenPharma Business Overview

Table 71. CordenPharma Peptide API CDMO Services Product

Table 72. CordenPharma Revenue in Peptide API CDMO Services Business (US$ Million), 2021–2026

Table 73. CordenPharma Recent Development

Table 74. CPC Scientific Company Details

Table 75. CPC Scientific Business Overview

Table 76. CPC Scientific Peptide API CDMO Services Product

Table 77. CPC Scientific Revenue in Peptide API CDMO Services Business (US$ Million), 2021–2026

Table 78. CPC Scientific Recent Development

Table 79. Piramal Pharma Solutions Company Details

Table 80. Piramal Pharma Solutions Business Overview

Table 81. Piramal Pharma Solutions Peptide API CDMO Services Product

Table 82. Piramal Pharma Solutions Revenue in Peptide API CDMO Services Business (US$ Million), 2021–2026

Table 83. Piramal Pharma Solutions Recent Development

Table 84. Almac Group Company Details

Table 85. Almac Group Business Overview

Table 86. Almac Group Peptide API CDMO Services Product

Table 87. Almac Group Revenue in Peptide API CDMO Services Business (US$ Million), 2021–2026

Table 88. Almac Group Recent Development

Table 89. Vtides Life Sciences Company Details

Table 90. Vtides Life Sciences Business Overview

Table 91. Vtides Life Sciences Peptide API CDMO Services Product

Table 92. Vtides Life Sciences Revenue in Peptide API CDMO Services Business (US$ Million), 2021–2026

Table 93. Vtides Life Sciences Recent Development

Table 94. Aspen Holdings Company Details

Table 95. Aspen Holdings Business Overview

Table 96. Aspen Holdings Peptide API CDMO Services Product

Table 97. Aspen Holdings Revenue in Peptide API CDMO Services Business (US$ Million), 2021–2026

Table 98. Aspen Holdings Recent Development

Table 99. Neuland Laboratories Company Details

Table 100. Neuland Laboratories Business Overview

Table 101. Neuland Laboratories Peptide API CDMO Services Product

Table 102. Neuland Laboratories Revenue in Peptide API CDMO Services Business (US$ Million), 2021–2026

Table 103. Neuland Laboratories Recent Development

Table 104. USV Company Details

Table 105. USV Business Overview

Table 106. USV Peptide API CDMO Services Product

Table 107. USV Revenue in Peptide API CDMO Services Business (US$ Million), 2021–2026

Table 108. USV Recent Development

Table 109. Aurigene Pharmaceutical Services Company Details

Table 110. Aurigene Pharmaceutical Services Business Overview

Table 111. Aurigene Pharmaceutical Services Peptide API CDMO Services Product

Table 112. Aurigene Pharmaceutical Services Revenue in Peptide API CDMO Services Business (US$ Million), 2021–2026

Table 113. Aurigene Pharmaceutical Services Recent Development

Table 114. CBL Company Details

Table 115. CBL Business Overview

Table 116. CBL Peptide API CDMO Services Product

Table 117. CBL Revenue in Peptide API CDMO Services Business (US$ Million), 2021–2026

Table 118. CBL Recent Development

Table 119. Provepharm Company Details

Table 120. Provepharm Business Overview

Table 121. Provepharm Peptide API CDMO Services Product

Table 122. Provepharm Revenue in Peptide API CDMO Services Business (US$ Million), 2021–2026

Table 123. Provepharm Recent Development

Table 124. PeptiStar Company Details

Table 125. PeptiStar Business Overview

Table 126. PeptiStar Peptide API CDMO Services Product

Table 127. PeptiStar Revenue in Peptide API CDMO Services Business (US$ Million), 2021–2026

Table 128. PeptiStar Recent Development

Table 129. Creative Peptides Company Details

Table 130. Creative Peptides Business Overview

Table 131. Creative Peptides Peptide API CDMO Services Product

Table 132. Creative Peptides Revenue in Peptide API CDMO Services Business (US$ Million), 2021–2026

Table 133. Creative Peptides Recent Development

Table 134. Space Peptides Company Details

Table 135. Space Peptides Business Overview

Table 136. Space Peptides Peptide API CDMO Services Product

Table 137. Space Peptides Revenue in Peptide API CDMO Services Business (US$ Million), 2021–2026

Table 138. Space Peptides Recent Development

Table 139. Cambrex Company Details

Table 140. Cambrex Business Overview

Table 141. Cambrex Peptide API CDMO Services Product

Table 142. Cambrex Revenue in Peptide API CDMO Services Business (US$ Million), 2021–2026

Table 143. Cambrex Recent Development

Table 144. ScinoPharm Company Details

Table 145. ScinoPharm Business Overview

Table 146. ScinoPharm Peptide API CDMO Services Product

Table 147. ScinoPharm Revenue in Peptide API CDMO Services Business (US$ Million), 2021–2026

Table 148. ScinoPharm Recent Development

Table 149. Chinese Peptide Company Company Details

Table 150. Chinese Peptide Company Business Overview

Table 151. Chinese Peptide Company Peptide API CDMO Services Product

Table 152. Chinese Peptide Company Revenue in Peptide API CDMO Services Business (US$ Million), 2021–2026

Table 153. Chinese Peptide Company Recent Development

Table 154. ChengDu ShengNuo Biotec Company Details

Table 155. ChengDu ShengNuo Biotec Business Overview

Table 156. ChengDu ShengNuo Biotec Peptide API CDMO Services Product

Table 157. ChengDu ShengNuo Biotec Revenue in Peptide API CDMO Services Business (US$ Million), 2021–2026

Table 158. ChengDu ShengNuo Biotec Recent Development

Table 159. WuXi TIDES Company Details

Table 160. WuXi TIDES Business Overview

Table 161. WuXi TIDES Peptide API CDMO Services Product

Table 162. WuXi TIDES Revenue in Peptide API CDMO Services Business (US$ Million), 2021–2026

Table 163. WuXi TIDES Recent Development

Table 164. Genscript Company Details

Table 165. Genscript Business Overview

Table 166. Genscript Peptide API CDMO Services Product

Table 167. Genscript Revenue in Peptide API CDMO Services Business (US$ Million), 2021–2026

Table 168. Genscript Recent Development

Table 169. Research Programs/Design for This Report

Table 170. Key Data Information from Secondary Sources

Table 171. Key Data Information from Primary Sources

Table 172. Authors List of This Report

List of Figures

Figure 1. Peptide API CDMO Services Picture

Figure 2. Global Peptide API CDMO Services Market Size Comparison by Type (US$ Million), 2021–2032

Figure 3. Global Peptide API CDMO Services Market Share by Type: 2025 vs 2032

Figure 4. GMP Services Features

Figure 5. Non-GMP Services Features

Figure 6. Global Peptide API CDMO Services Market Size Comparison by Synthesis Technology (US$ Million), 2021–2032

Figure 7. SPPS Features

Figure 8. LPPS Features

Figure 9. Hybrid Technology Features

Figure 10. Global Peptide API CDMO Services Market Size Comparison by Capacity Tier (US$ Million), 2021–2032

Figure 11. Small-Scale (mg–g) Features

Figure 12. Medium-Scale (g–kg) Features

Figure 13. Large-Scale (kg–t) Features

Figure 14. Global Peptide API CDMO Services Market Size by Application (US$ Million), 2021–2032

Figure 15. Global Peptide API CDMO Services Market Share by Application: 2025 vs 2032

Figure 16. Commercial Case Studies

Figure 17. Scientific Research Case Studies

Figure 18. Other Case Studies

Figure 19. Peptide API CDMO Services Report Years Considered

Figure 20. Global Peptide API CDMO Services Market Size (US$ Million), Year-over-Year: 2021–2032

Figure 21. Global Peptide API CDMO Services Market Size, (US$ Million), 2021 vs 2025 vs 2032

Figure 22. Global Peptide API CDMO Services Market Share by Region: 2025 vs 2032

Figure 23. Global Peptide API CDMO Services Market Share by Players in 2025

Figure 24. Global Peptide API CDMO Services Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

Figure 25. The Top 10 and 5 Players Market Share by Peptide API CDMO Services Revenue in 2025

Figure 26. North America Peptide API CDMO Services Market Size YoY Growth (US$ Million), 2021–2032

Figure 27. North America Peptide API CDMO Services Market Share by Country (2021–2032)

Figure 28. United States Peptide API CDMO Services Market Size YoY Growth (US$ Million), 2021–2032

Figure 29. Canada Peptide API CDMO Services Market Size YoY Growth (US$ Million), 2021–2032

Figure 30. Europe Peptide API CDMO Services Market Size YoY Growth (US$ Million), 2021–2032

Figure 31. Europe Peptide API CDMO Services Market Share by Country (2021–2032)

Figure 32. Germany Peptide API CDMO Services Market Size YoY Growth (US$ Million), 2021–2032

Figure 33. France Peptide API CDMO Services Market Size YoY Growth (US$ Million), 2021–2032

Figure 34. U.K. Peptide API CDMO Services Market Size YoY Growth (US$ Million), 2021–2032

Figure 35. Italy Peptide API CDMO Services Market Size YoY Growth (US$ Million), 2021–2032

Figure 36. Russia Peptide API CDMO Services Market Size YoY Growth (US$ Million), 2021–2032

Figure 37. Ireland Peptide API CDMO Services Market Size YoY Growth (US$ Million), 2021–2032

Figure 38. Asia-Pacific Peptide API CDMO Services Market Size YoY Growth (US$ Million), 2021–2032

Figure 39. Asia-Pacific Peptide API CDMO Services Market Share by Region (2021–2032)

Figure 40. China Peptide API CDMO Services Market Size YoY Growth (US$ Million), 2021–2032

Figure 41. Japan Peptide API CDMO Services Market Size YoY Growth (US$ Million), 2021–2032

Figure 42. South Korea Peptide API CDMO Services Market Size YoY Growth (US$ Million), 2021–2032

Figure 43. Southeast Asia Peptide API CDMO Services Market Size YoY Growth (US$ Million), 2021–2032

Figure 44. India Peptide API CDMO Services Market Size YoY Growth (US$ Million), 2021–2032

Figure 45. Australia & New Zealand Peptide API CDMO Services Market Size YoY Growth (US$ Million), 2021–2032

Figure 46. Latin America Peptide API CDMO Services Market Size YoY Growth (US$ Million), 2021–2032

Figure 47. Latin America Peptide API CDMO Services Market Share by Country (2021–2032)

Figure 48. Mexico Peptide API CDMO Services Market Size YoY Growth (US$ Million), 2021–2032

Figure 49. Brazil Peptide API CDMO Services Market Size YoY Growth (US$ Million), 2021–2032

Figure 50. Middle East & Africa Peptide API CDMO Services Market Size YoY Growth (US$ Million), 2021–2032

Figure 51. Middle East & Africa Peptide API CDMO Services Market Share by Country (2021–2032)

Figure 52. Israel Peptide API CDMO Services Market Size YoY Growth (US$ Million), 2021–2032

Figure 53. Saudi Arabia Peptide API CDMO Services Market Size YoY Growth (US$ Million), 2021–2032

Figure 54. UAE Peptide API CDMO Services Market Size YoY Growth (US$ Million), 2021–2032

Figure 55. PolyPeptide Revenue Growth Rate in Peptide API CDMO Services Business (2021–2026)

Figure 56. Bachem Revenue Growth Rate in Peptide API CDMO Services Business (2021–2026)

Figure 57. AmbioPharm Revenue Growth Rate in Peptide API CDMO Services Business (2021–2026)

Figure 58. CordenPharma Revenue Growth Rate in Peptide API CDMO Services Business (2021–2026)

Figure 59. CPC Scientific Revenue Growth Rate in Peptide API CDMO Services Business (2021–2026)

Figure 60. Piramal Pharma Solutions Revenue Growth Rate in Peptide API CDMO Services Business (2021–2026)

Figure 61. Almac Group Revenue Growth Rate in Peptide API CDMO Services Business (2021–2026)

Figure 62. Vtides Life Sciences Revenue Growth Rate in Peptide API CDMO Services Business (2021–2026)

Figure 63. Aspen Holdings Revenue Growth Rate in Peptide API CDMO Services Business (2021–2026)

Figure 64. Neuland Laboratories Revenue Growth Rate in Peptide API CDMO Services Business (2021–2026)

Figure 65. USV Revenue Growth Rate in Peptide API CDMO Services Business (2021–2026)

Figure 66. Aurigene Pharmaceutical Services Revenue Growth Rate in Peptide API CDMO Services Business (2021–2026)

Figure 67. CBL Revenue Growth Rate in Peptide API CDMO Services Business (2021–2026)

Figure 68. Provepharm Revenue Growth Rate in Peptide API CDMO Services Business (2021–2026)

Figure 69. PeptiStar Revenue Growth Rate in Peptide API CDMO Services Business (2021–2026)

Figure 70. Creative Peptides Revenue Growth Rate in Peptide API CDMO Services Business (2021–2026)

Figure 71. Space Peptides Revenue Growth Rate in Peptide API CDMO Services Business (2021–2026)

Figure 72. Cambrex Revenue Growth Rate in Peptide API CDMO Services Business (2021–2026)

Figure 73. ScinoPharm Revenue Growth Rate in Peptide API CDMO Services Business (2021–2026)

Figure 74. Chinese Peptide Company Revenue Growth Rate in Peptide API CDMO Services Business (2021–2026)

Figure 75. ChengDu ShengNuo Biotec Revenue Growth Rate in Peptide API CDMO Services Business (2021–2026)

Figure 76. WuXi TIDES Revenue Growth Rate in Peptide API CDMO Services Business (2021–2026)

Figure 77. Genscript Revenue Growth Rate in Peptide API CDMO Services Business (2021–2026)

Figure 78. Bottom-up and Top-down Approaches for This Report

Figure 79. Data Triangulation

Figure 80. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License

Multi User

Electronic

$4350

Multi User License

Enterprise License

Electronic

$5800

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Oligonucleotide Drug CDMO Services Market Research Report 2024

Global Formulation CDMO Services Market Research Report 2024

Global Pharmaceutical Contract Development and Manufacturing Organization Market Research Report 2025

Global Full Service CDMO Market Research Report 2024

Global Biopharmaceutical CDMO Service Market Research Report 2024

Global Peptide CDMO Services Market Research Report 2025

Global Peptide Synthesis CDMO Services Market Research Report 2024

Global Peptide Drug CDMO Market Research Report 2024

Global Custom Peptide CDMO Services Market Research Report 2024

Active Pharmaceutical Ingredients API CDMO Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Small Molecule Drug CDMO Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Pharmaceutical CMO and CDMO Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Small Molecule Drug CDMO Services Market Research Report 2024

Global Antibody Drug CDMO Service Market Research Report 2024

Peptide CDMO Pharmaceutical Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Chemical CDMO Market Research Report 2024

Global mRNA CDMO Service Market Research Report 2024

Global Peptide Drug Conjugates PDCs CDMO Service Market Research Report 2024

Global Small Molecules CDMO Services Market Research Report 2024

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions